A M Lincoff Selected Research

Percutaneous Coronary Intervention

7/2006	Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk.
2/2004	Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes.
1/2003	Abciximab and atherosclerotic heart disease: use in percutaneous coronary intervention, acute coronary syndromes and acute myocardial infarction.
7/2002	Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial.
2/2002	Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker.
7/2001	Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization.
7/2001	Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention.
5/2001	Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.
2/2001	Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators.
12/2000	Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

A M Lincoff Research Topics

Disease

25	Myocardial Infarction 07/2006 - 01/2000
17	Acute Coronary Syndrome 03/2005 - 02/2000
9	Hemorrhage 07/2006 - 04/2000
9	Unstable Angina 07/2002 - 02/2000
6	Infarction (Infarctions) 07/2002 - 03/2000
3	Ischemia 03/2005 - 01/2000
3	ST Elevation Myocardial Infarction 01/2003 - 04/2000
3	Diabetes Mellitus 08/2001 - 02/2000
3	Cardiovascular Diseases (Cardiovascular Disease) 07/2001 - 03/2001
2	Thrombocytopenia (Thrombopenia) 08/2001 - 07/2000
2	Myocardial Ischemia (Ischemic Heart Diseases) 03/2001 - 10/2000
2	Coronary Artery Disease (Coronary Atherosclerosis) 10/2000 - 04/2000
2	Heart Failure 10/2000 - 06/2000
1	Arthritis (Polyarthritis) 01/2018
1	Osteoarthritis 01/2018
1	Rheumatoid Arthritis 01/2018
1	Heart Diseases (Heart Disease) 01/2003
1	Non-ST Elevated Myocardial Infarction 07/2002
1	Hyperplasia 08/2001
1	Inflammation (Inflammations) 07/2001
1	Hemorrhagic Stroke 07/2001
1	Stroke (Strokes) 07/2001
1	Coronary Disease (Coronary Heart Disease) 04/2001
1	Left Ventricular Dysfunction 10/2000
1	Chest Pain (Chest Pains) 09/2000
1	Pathologic Constriction (Stenosis) 09/2000
1	Hypertension (High Blood Pressure) 03/2000
1	Insulin Resistance 03/2000
1	Obesity 03/2000
1	Coronary Thrombosis 02/2000

Drug/Important Bio-Agent (IBA)

15	Abciximab (ReoPro)FDA Link 01/2003 - 02/2000
14	Eptifibatide (Integrilin)FDA Link 07/2002 - 02/2000
12	Platelet Membrane GlycoproteinsIBA 02/2002 - 02/2000
9	Glycoproteins (Glycoprotein)IBA 10/2003 - 02/2000
8	Heparin (Liquaemin)FDA LinkGeneric 03/2005 - 04/2000
5	Platelet Membrane Glycoprotein IIbIBA 02/2001 - 02/2000
3	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 07/2001 - 04/2000
2	(2S)- 2- (4- (((3S)- 1- acetimidoyl- 3- pyrrolidinyl)oxy)phenyl)- 3- (7- amidino- 2- naphtyl)propanoic acidIBA 03/2005 - 02/2004
2	MB Form Creatine KinaseIBA 02/2004 - 09/2000
2	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 03/2000 - 02/2000
1	Celecoxib (Celebrex)FDA Link 01/2018
1	Naproxen (Naprosyn)FDA LinkGeneric 01/2018
1	Esomeprazole (Nexium)FDA Link 01/2018
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2018
1	Ibuprofen (Motrin)FDA LinkGeneric 01/2018
1	Factor Xa InhibitorsIBA 03/2005
1	Factor Xa (Coagulation Factor Xa)IBA 03/2005
1	Creatine Kinase (Creatine Phosphokinase)IBA 02/2004
1	Streptozocin (Streptozotocin)FDA Link 08/2001
1	P-SelectinIBA 08/2001
1	Immunoglobulins (Immunoglobulin)IBA 08/2001
1	Phenobarbital (Luminal)FDA Link 08/2001
1	LigandsIBA 08/2001
1	GoldIBA 05/2001
1	LipidsIBA 04/2001
1	Ticlopidine (Ticlid)FDA LinkGeneric 03/2001
1	Fibrinolytic Agents (Antithrombotic Agents)IBA 02/2001
1	reteplase FDA Link 11/2000
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 10/2000
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 10/2000
1	EnzymesIBA 06/2000
1	AntithrombinsIBA 04/2000
1	Tirofiban (Aggrastat)FDA Link 04/2000
1	tranilastIBA 01/2000

Therapy/Procedure

18	Percutaneous Coronary Intervention 07/2006 - 02/2000
15	Therapeutics 10/2003 - 03/2000
1	Platelet Transfusion (Blood Platelet Transfusions) 08/2001
1	Retreatment 08/2001
1	Drug Tapering 12/2000
1	Operative Surgical Procedures 08/2000
1	Stents 07/2000